37 results about "CYP2C9" patented technology

The invention relates to a medicine metabolic relevant loci detection method, which comprises the following steps: extracting genome DNA from human samples; respectively designing a Taqman probe pair and a primer pair according to at least two medicine metabolic relevant genes; respectively marking the 5' end and the 3'end of the Taqman probe pair with fluorescence reporting genes and fluorescence quenching genes; carrying out fluorescence quantitative PCR augmentation on the genome DNA; and judging whether the medicine metabolic relevant genes have the mutation according to the fluorescence quantitative PCR augmentation results. Preferably, the number of the medicine metabolic relevant genes is four, the Taqman probe pair and the primer pair are used for detecting a loci rs1057910 of a gene CYP2C9, a loci rs4244285 of a gene CYP2C19, a loci rs4986893of a gene CYP2C19, a loci rs1065852 of a gene CYP2D6 and a loci rs28371759 of a gene CYP3A4. The invention has the advantages of ingenious design, simple operation and accurate and reliable detection results, and provides the reference frame for determining whether professional doctors are needed to be consulted so as to make sure the medicine can be taken or not or the proper dosage and the like when a certain medicine is taken.

The invention relates to the technical field of DNA detection and provides an SNP typing method and kit. A to-be-tested SNP site comprises SNP sites in CYP2C9, VKORC1 and CYP2C19 genes. The SNP typing method comprises the following steps: replacing a fluorescently-labeled oligonucleotide probe with a non-fluorescently-labeled oligonucleotide probe, performing one-time connection sequencing reaction on to-be-sequenced library molecules and then obtaining sequence information of the to-be-tested SNP site through connection sequencing. The SNP typing kit comprises a CYP2C9 specific primer pair, a VKORC1 specific primer pair, a CYP2C19 specific primer pair and the non-fluorescently-labeled oligonucleotide probe. The SNP typing method and kit provided by the invention have the benefit that through sealing non-specific binding sites in the to-be-sequenced library molecules, a false signal in a result obtained by the connection sequencing is reduced, so that the accuracy of SNP site detection is improved.

The invention belongs to the field of biology, relates to single-base mutation and particularly relates to a 1300th bit mutation site of a CYP2C9 gene corresponding to SEQ ID NO.2. The 1300th bit mutation site is mutated from wild type A into T. The invention relates to a nucleic acid fragment containing the 1300th bit mutation site, a protein fragment encoded through the same and application thereof. The invention also provides allelomorphic gene specific oligonucleotide for detecting the 1300th bit mutation site, a kit and a detection method.

The invention relates to a SNP site detection kit for guiding diabetes medication and use method thereof. The kit includes an amplification PCR reaction system, the amplification PCR reaction system comprises a PCR premix liquid and a plurality of pairs of PCR primers, through the multiple pairs of the PCR primers, 10 sites of 8 genes can be simultaneously detected, namely CYP2C9(rs1057910), KCNJ11(rs5219), ABCC8(rs757110, rs1799854), TCF7L2(rs12255372, rs7903146), SLC22A1(rs72552763), SLC22A2(rs316019), PPARG(rs1801282), and SLCO1B1(rs4149056), and the sequencing results guide the diabetes medication for patients. The 10 sites are detect and simultaneously amplified by adopting the method of multiplex PCR amplification, and the single reaction system amplification not only simplifies theoperation, reduces the possibility of errors, but also reduces the experiment cost. In addition, the guiding medication of the present invention cover four major classes of diabetes drugs: sulfonylureas, biguanides, thiazolidinediones and meglitinides, and the detection and analysis of 10 sites of related genes is more extensive than similar products on the market.

The invention provides a primer for detecting CYP2C9*2 gene polymorphism. The primer for detecting CYP2C9*2 gene polymorphism comprises a PCR amplification primer and a SNaPshot PCR primer. The primer for detecting CYP2C9*2 gene polymorphism belongs to the technical field of biological detection. The primer for detecting CYP2C9*2 gene polymorphism can achieve the specific detection on the CYP2C9*2 gene polymorphism, and the accuracy is good.

The invention relates to the technical field of medicine and biology, and discloses a primer set and a kit for detecting polymorphism of hyperglycemia drug metabolism related genes and application ofthe primer set and the kit. The primer set comprises primers capable of amplifying at least one hyperglycemia drug metabolism related gene: CYP2C9, KCNJ11, PPARgamma, SLCO1B1, SLC22A1, SLC22A2, and APOE. The primer set can also comprise a sequencing primer for carrying out Sanger sequencing on at least one of the above genes. The primer set and kit can formulate different schemes for hyperglycemiapatients according to individual differences of genes, select appropriate hypoglycemic drugs, realize accurate typing and precise medication, thereby increase hypoglycemic effect and reduce adverse drug reactions. The preferred primer set has high sensitivity and specificity, and when the preferred primer set is used for genotyping genes related to hyperglycemia drug metabolism, the primer set has advantages of being accurate in qualitative analysis, high in specificity and the like.

The invention relates to a medicine metabolic relevant loci detection method, which comprises the following steps: extracting genome DNA from human samples; respectively designing a Taqman probe pair and a primer pair according to at least two medicine metabolic relevant genes; respectively marking the 5' end and the 3'end of the Taqman probe pair with fluorescence reporting genes and fluorescence quenching genes; carrying out fluorescence quantitative PCR augmentation on the genome DNA; and judging whether the medicine metabolic relevant genes have the mutation according to the fluorescence quantitative PCR augmentation results. Preferably, the number of the medicine metabolic relevant genes is four, the Taqman probe pair and the primer pair are used for detecting a loci rs1057910 of a gene CYP2C9, a loci rs4244285 of a gene CYP2C19, a loci rs4986893of a gene CYP2C19, a loci rs1065852 of a gene CYP2D6 and a loci rs28371759 of a gene CYP3A4. The invention has the advantages of ingenious design, simple operation and accurate and reliable detection results, and provides the reference frame for determining whether professional doctors are needed to be consulted so as to make sure themedicine can be taken or not or the proper dosage and the like when a certain medicine is taken.

A near-infrared fluorescent probe for detecting cytochrome P450 2C9 and its application belong to the technical field of biomedicine. The specific probe substrate can be used to measure the enzymatic activity of CYP2C9 in biological systems. The process of CYP2C9 enzyme activity determination is as follows: 1,3-dichloro-7-alkoxy-9,9-dimethyl-2(9H)-acridone was selected O The dealkylation reaction is a probe reaction, which quantitatively detects the elimination amount of the substrate 1,3-dichloro-7-alkoxy-9,9-dimethyl-2(9H)-acridone in unit time The activity of CYP2C9 enzymes in various biological samples was determined by the amount of its dealkylated metabolites. The invention can be used for quantitative assessment of CYP2C9 enzyme activity in biological samples from different sources, species and individuals and imaging of CYP2C9 in organisms, so as to realize the assessment of CYP2C9's ability to dispose of drugs. It can also be used for rapid in vitro screening of CYP2C9 activity modulators, and to evaluate the potential of drug-drug interactions due to inhibition or activation of CYP2C9 catalytic activity, such as drugs and candidate compounds.

The present invention relates to oligonucleotide sequences for amplification primers and detection probes and their use in nucleic acid amplification methods for the specific detection of clinically relevant CYP2C9 polymorphisms, in particular CYP2C9 polymorphisms associated with adverse drug response. The oligonucleotide sequences are also provided assembled as kits that can be used to predict how an individual will respond to drugs or other xenobiotic compounds that are metabolized, at least in part, by CYP2C9.

The invention discloses a specific primer and liquid phase chip for SNP (Single Nucleotide Polymorphism) detection of CYP2C9 (Cytochrome P4502C9), wherein the liquid phase chip comprises an ASPE primer consisting of a tag sequence of 5' end and a specific primer of 3' end aiming at target gene mutation, a microsphere coated by the anti-tag sequence, and an amplification primer; the specific primer includes: SEQ ID NO.17 and SEQ ID NO.18 aiming at G98A SNP locus, SEQ ID NO.19 and SEQ ID NO.20 aiming at G173A SNP locus, SEQ ID NO.21 and SEQ ID NO.22 aiming at C90T SNP locus, SEQ ID NO.23 and SEQ ID NO.24 aiming at A162C SNP locus, SEQ ID NO.25 and SEQ ID NO.26 aiming at C72T SNP locus, SEQ ID NO.27 and SEQ ID NO.28 aiming at T102C SNP locus, SEQ ID NO.29 and SEQ ID NO.30 aiming at A77G SNP locus, and / or SEQ ID NO.31 and SEQ ID NO.32 aiming at A167C SNP locus. The matching rate between a detection result obtained by adopting the liquid phase chip for SNP detection of CYP2C9 and a sequencing method can be 100%.

The invention belongs to the field of biology, relates to single-base mutation, and in particular relates to a CYP2C9 gene which is corresponding to the mutation site mutated from wild type T into C on the 1400th bit of SEQ ID NO.2, a nucleic acid segment containing the mutation site, a protein segment coded by the nucleic acid segment and application thereof. The invention also provides allele specific oligonucleotide, a kit and a detection method for detecting the mutation site.

The invention relates to a method for detecting CYP2C9 enzyme activity in earthworms by adopting a high-performance liquid chromatography-tandem mass spectrometry and belongs to the technical field of enzyme activity detection. The method specifically comprises the following steps: (1) preparing earthworm microsome protein suspension; (2) adding the earthworm microsome protein suspension prepared in the step (1) into an incubation system containing a probe substrate; raising the temperature to start an enzymatic reaction; after the enzymatic reaction is stopped, detecting a metabolic product, which is generated after the enzymatic reaction is stopped, by adopting the high-performance liquid chromatography-tandem mass spectrometry; calculating the CYP2C9 enzyme activity. The detection method is high in accuracy, precision and sensitivity and high in stability, and can be used for analyzing and detecting the CYP2C9 enzyme activity in the earthworms under different pollution environments, so that a detection method for probing the possibility of taking CYP2C9 as a biological marker to indicate soil pollution is provided.